Bongki Park,Sooseong You,William C. S. Cho,Jun-Yong Choi,Myeong Soo Lee
2019, 20(1): 9-22. DOI: 10.1631/jzus.B1800171
摘要:本综述总结利用中草药治疗癌症恶病质的临床前研究及其潜在的机制,是首个针对中草药治疗癌症恶病质动物模型成效进行系统性回顾评价的研究.本文通过检索PubMed、EMBASE、Allied and Complementary Medicine Database以及Web of Science四大代表性的资料库(检索时间至2016年12月),就中草药治疗癌症恶病质的随机对照动物试验进行系统性回顾分析,并采用CAMARADE评分清单进行质量评价.分析结果显示:在十四项中草药及其化合物中,除了姜黄素外其他如黄连、黄连素、病得灵、清暑益气汤、黄芩、补中益气汤、六君子汤、橙皮苷、苍术呋喃烃、十全大补汤、小柴胡汤、知母及黄柏等都已被证实可以通过抗炎、调节神经内分泌途径、调节泛素蛋白酶体系统或蛋白质合成来改善癌症恶病质的症状.因此,利用中草药治疗癌症恶病质是一种有效的方法.然而该结论尚需要有更详细的分子机制和活性化合物的实验研究验证.
摘要:The rapid developments of science and technology in China over recent decades, particularly in biomedical research, have brought forward serious challenges regarding ethical governance. Recently, Jian-kui HE, a Chinese scientist, claimed to have “created” the first gene-edited babies, designed to be naturally immune to the human immunodeficiency virus (HIV). The news immediately triggered widespread criticism, denouncement, and debate over the scientific and ethical legitimacy of HE’s genetic experiments. China’s guidelines and regulations have banned germline genome editing on human embryos for clinical use because of scientific and ethical concerns, in accordance with the international consensus. HE’s human experimentation has not only violated these Chinese regulations, but also breached other ethical and regulatory norms. These include questionable scientific value, unreasonable risk-benefit ratio, illegitimate ethics review, invalid informed consent, and regulatory misconduct. This series of ethical failings of HE and his team reveal the institutional failure of the current ethics governance system which largely depends on scientist’s self-regulation. The incident highlights the need for urgent improvement of ethics governance at all levels, the enforcement of technical and ethical guidelines, and the establishment of laws relating to such bioethical issues.